<DOC>
	<DOCNO>NCT01674413</DOCNO>
	<brief_summary>This study invite adult Crohn 's disease respond well Adalimumab ( Humira ® ) least 6 month . Patients frequently discontinue maintenance medication Crohn 's disease , particularly remission . Patients want know truly need take medication , yet n't want flare . The purpose study see monitor patient , along look change stool sample , safely stop maintenance medication Adalimumab 48 week , add as-needed dosing , keep remission .</brief_summary>
	<brief_title>Calprotectin-Directed Humira® Maintenance Therapy ( CADHUM )</brief_title>
	<detailed_description>Patients frequently discontinue maintenance medication Crohn 's disease , particularly remission . Patients want know truly need take medication , yet n't want flare . As biomarker , fecal calprotectin &lt; 167 100 % negative predictive value flare within next 12 week ( Gisbert , 2009 ) . Adalimumab low antigenicity , safely stop restart later good clinical effect ( Colombel , 2007 ) . Patients want intermittent therapy , deliver timely fashion pre-clinical inflammation start , order avoid clinically-significant flare . This study combine monitoring pre-clinical inflammation fecal calprotectin as-needed dosing Adalimumab maintain remission patient obtain remission Adalimumab . This compare two comparator arm : standard maintenance therapy complete cessation therapy ( Step-Down approach ) .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>1 . Men woman 18 year age old time inform consent . 2 . Crohn 's disease confirm endoscopy biopsy . 3 . On maintenance Adalimumab dose 40 mg SC q 2 week without concomitant immunosuppressive therapy . 4 . Must clinical remission ( CDAI &lt; 150 ) baseline/randomization ( Week 0 ) visit biologic remission ( CRP &lt; 0.8 FCP &lt; 167 ) Week 0 . 5 . Prior medication Crohn 's disease may include one follow must stop wash period : Methotrexate , Azathioprine , 6Mercaptopurine , Tacrolimus , Steroids . 6 . Negative TB , Hepatitis Bnegative , negative stool Clostridium difficile . Exclusion Criteria 1 . Unable consent . 2 . Are prisoner , student employee investigator , mentally incapacitate . 3 . Are unwilling complete 48 week study , provide stool sample throughout , unwilling undergo multiple venipuncture . 4 . Have current infection Clostridium difficile , clinicallysignificant intestinal stricture , history allergy , adverse reaction , Adalimumab , history sensitivity latex . 5 . Are currently use steroid systemic immunomodulators ( MTX , AZA , 6MP , Tacrolimus ) , use another biologic medication past 12 week Adalimumab , current past use Kineret® ( Anakinra ) Tysabri® ( natalizumab ) . 6 . Have receive live bacterial viral vaccination ≤ 12 week prior Week 0 must receive 12 month study well BCG vaccination 7 . Are known congestive heart failure . 8 . Have history , ongoing chronic recurrent infectious disease , include limited chronic renal , chest infection ( i.e . bronchiectasis ) urinary tract infection ( i.e . recurrent pyelonephritis ) open , drain , infected skin wound ulcer . 9 . Have evidence current clinically active important infection . 10 . Have ever nontuberculous mycobacterium infection serious opportunistic infection ( i.e . cytomegalovirus , Pneumocystis carinii , aspergillosis ) . 11 . Are know infected HIV , Hepatitis B , Hepatitis C. 12 . Have severe , progressive , uncontrolled renal , hepatic , hematological , endocrine , pulmonary , cardiac , neurologic , cerebral , psychiatric disease , sign symptom thereof . 13 . Have know history lymphoproliferative disease include lymphoma . Have history certain malignancy within five year screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Crohn 's Disease</keyword>
	<keyword>Crohn 's</keyword>
	<keyword>Crohns</keyword>
	<keyword>Inflammatory Bowel Disease</keyword>
	<keyword>IBD</keyword>
	<keyword>Humira</keyword>
	<keyword>Adalimumab</keyword>
	<keyword>Adalimumab injection</keyword>
	<keyword>Higgins</keyword>
	<keyword>Calprotectin</keyword>
	<keyword>biomarkers</keyword>
	<keyword>Gastroenterology</keyword>
	<keyword>University Michigan</keyword>
	<keyword>U M</keyword>
</DOC>